This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DVA Stock Down in Pre-Market Despite Q4 Earnings Beat, Margins Expand
by Zacks Equity Research
Robust segmental revenues drive DaVita's fourth-quarter 2024 performance despite a per-day decrease of the total U.S. dialysis treatments on a sequential basis.
DaVita HealthCare (DVA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 1.36% and 1.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DVA Q4 Estimates Unchanged Before Earnings: How to Play the Stock?
by Zacks Equity Research
Continued strength in RPT is likely to have boosted DaVita's top line in the fourth quarter despite supply challenges weighing on its performance.
DaVita HealthCare (DVA) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $177.35, representing a +0.16% change from its previous close.
GEHC Stock May Gain on FDA's Nod for the Updated Voluson Expert Series
by Zacks Equity Research
GE HealthCare launches the enhanced Voluson Expert Series to advance women's health with faster, more precise imaging for improved care in obstetrics and gynecology.
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.
ANGO Stock Looks Promising on New Ischemia Study for Auryon System
by Zacks Equity Research
AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease.
4 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like ENS, DVA, REVG and PAA are seeing price strength and the momentum is likely to continue.
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
by Zacks Equity Research
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $173.77, denoting a +0.32% change from the preceding trading day.
DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
by Zacks Equity Research
SYK announces agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC.
Is CareDx (CDNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CareDx (CDNA) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach
by Zacks Equity Research
INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.
Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Zacks Investment Ideas feature highlights: Nvidia, Vertiv, Vistra and DaVita
by Zacks Equity Research
Nvidia, Vertiv, Vistra and DaVita are part of the Zacks Investment Ideas article.
Top Stock Picks for Week of January 27, 2025
by Panel Of Zacks Experts
A Strong Buy Financial Stock with a Good Momentum Score and a Strong Buy Home Healthcare Provider with an Impressive Value Score.
Sell Nvidia, Buy This Stock
by Ethan Feller
Nvidia and other AI leaders are selling off today while defensive stocks like DaVita make record highs
VEEV Stock Falls Despite Tie-Up to Streamline Customers' Operations
by Zacks Equity Research
Veeva Systems aims to simplify master data configuration during LIMS implementation and site deployment and enable companies to advance beyond legacy QC systems.
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $169.90 in the latest trading session, marking a +0.86% move from the prior day.
Masimo Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.
Is DaVita (DVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $166.24, signifying a +0.84% move from its prior day's close.
Zacks Industry Outlook Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.